Psychiatric comorbidities are identified in inflammatory bowel diseases. Recent studies show that the brain-gut-microbiota axis may provide  an insight to the pathophysiology of depression.The purpose of this systematic review is to identify a connection between brain-gut-microbiota axis interactions and depressive disorders. The research method was systematic review following the guidelines of the PRISMA systematic reviews and meta-analyzes.The brain-gut-microbiome axis allows bidirectional communications between the central nervous system and the gut. Dysregulation of the brain-gut-microbiome axis is implicated in a variety of psychological and gastrointestinal diseases (1, 2).In terms of gut-to-brain signaling, there is emerging evidence from preclinical and  clinical observation that intestinal inflammation alters brain functions, including the induction of mood disorders. Furthermore, preclinical studies suggest that effective treatment of intestinal inflammation improves associated behavioral impairment (3). A growing range of treatments targeting inflammation centrally, peripherally and the gut, inflammatory bowel diseases provides a unique model to understand the interplay between brain and gut in the pathogenesis of depressive symptoms, both in IBD and whole population(4).The new treatment avenues could be addressed through the modulation of the microbiota-gut-brain axis by means of prebiotic and probiotic administration (5). New researches are nedeed.

Acknowledgements: “The work of the first author is supported by the project ANTREPRENORDOC, in the framework of Human Resources Development Operational Programme 2014-2020, financed from the European Social Fund under the contract number 36355/23.05.2019 HRD OP /380/6/13 – SMIS Code: 123847. The work of the second author was carried out in the framework of the research project DREAM (Dynamics of the REsources and technological Advance in harvesting Marine renewable energy), supported by the Romanian Executive Agency for Higher Education, Research, Development and Innovation Funding – UEFISCDI, grant number PN-III-P4-ID- PCE-2020-0008.”